Anti-α4β7 Integrin (Vedolizumab), Humanized Antibody
Catalogue number:
A2140-100
Supplier:
BioVision
Size:
100 µg _$$_
Product is available in:
N/A
Shipping is calculated in checkout
This product is no longer available to order.
Applications:
In vitro studies
Antibody Host:
Recombinant
Species Reactivity:
Human
Antibody Isotype:
IgG1, kappa
Antibody Type:
Monoclonal
Immunogen:
Vedolizumab
- Data sheet: View or download
Product Description:
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody that selectively targets α4β7 integrin expressed on the surface of T and B cell lymphocytes and prevents the association of the integrin with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This inhibits the inflammatory activity of the lymphocytic cells and its migration into the gut lamina propria and gut-associated lymphoid tissue (GALT). Vedolizumab was developed by Millennium Pharmaceuticals and received FDA approval in 2014 for the treatment of ulcerative colitis and Crohn’s disease. Vedolizumab is marketed under the trade name of Entyvio®
Storage Temperature:
-80°C